Aprea Therapeutics (Aprea Therapeutics) Float Percentage Of Total Shares Outstanding : 57.92% (As of Apr. 28, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Aprea Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aprea Therapeutics's float shares is 3.15 Mil. Aprea Therapeutics's total shares outstanding is 5.43 Mil. Aprea Therapeutics's float percentage of total shares outstanding is 57.92%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aprea Therapeutics's Insider Ownership is 31.82%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aprea Therapeutics's Institutional Ownership is 5.38%.

Aprea Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Aprea Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	3.15	/	5.43
	=	57.92%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprea Therapeutics (Aprea Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprea Therapeutics Inc (NAS:APRE) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

3805 Old Easton Road, Doylestown, PA, USA, 18902

Website

https://www.aprea.com

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).

Executives

Jean-pierre Bizzari	director	235 LAUREL LN, HAVERFOLD PA 19041
Bernd R. Seizinger	director	535 BOYLSTON STREET, BOSTON MA 02116
Gabriela Gruia	director	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
John P. Hamill	officer: SrVP/CFO/Prin. Fin &Acctg. Off	4092 NEW HOPE ROAD, FURLONG PA 18925
Michael Grissinger	director	C/O RESTORBIO, INC., 500 BOYLSTON ST., 12TH FLOOR, BOSTON MA 02116
Marc Duey	director	27 STRATHMORE ROAD, NATICK MA 01760
Oren Gilad	officer: President, CEO	535 BOYLSTON STREET, BOSTON MA 02116
Rifat Pamukcu	director	535 BOYLSTON STREET, BOSTON MA 02116
Christian S Schade	director, officer: President & CEO	MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Eyal C. Attar	officer: SVP, Chief Medical Officer	535 BOYLSTON STREET, BOSTON MA 02116
Gregory Alan Korbel	officer: Chief Business Officer	535 BOYLSTON STREET, BOSTON MA 02116
Lars B. Abrahmsen	officer: SVP, Chief Scientific Officer	535 BOYLSTON STREET, BOSTON MA 02116
Jeremy Green	10 percent owner	45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Redmile Group, Llc	10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
5am Ventures Iv, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107